Apoptotic effects of signal transduction inhibitors on human tumor cells with different PTEN expression

Oncology Reports

Volumn 18, Issue 5, 2007, Pages 1305-1309

  Pfeiler, Georg ^a   Horn, Felicitas ^a   Lattrich, Claus ^a   Klappenberger, Stefanie ^a   Ortmann, Olaf ^a   Treeck, Oliver ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Apoptosis; Cancer cells; Mitogen activated protein kinase; PTEN; Targeted therapy

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVONOID; GEFITINIB; HER1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE (CALCIUM,CALMODULIN); PTEN PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELL LINE, TUMOR; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FLAVONOIDS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 38449083549     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.5.1305     Document Type: Article

References (20)

1. Perry RR, Kang Y and Greaves B: Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 2: 238-245, 1995.
2. Nahta R, Hung MC and Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64: 2343-2346, 2004. (Pubitemid 38523885)
3. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP and Eng C: Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92: 924-930, 2000.
4. Risinger JI, Hayes AK, Berchuck A and Barrett JC: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57: 4736-4738, 1997. (Pubitemid 27468978)
5. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S and Mori M: Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 68: 398-404, 2005. (Pubitemid 41160970)
6. Saito M, Okamoto A, Kohno T, Takakura S, Shinozaki H, Isonishi S, Yasuhara T, Yoshimura T, Ohtake Y, Ochiai K, Yokota J and Tanaka T: Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 85: 160-165, 2000. (Pubitemid 30023061)
7. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP and Tonks NK: The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 95: 13513-13518, 1998. (Pubitemid 28523003)
8. Weng LP, Brown JL and Eng C: PTEN coordinates G (1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 10: 599-604, 2001. (Pubitemid 32229364)
9. Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K and Yamada KM: Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 146: 389-403, 1999. (Pubitemid 29369775)
10. Gu J, Tamura M and Yamada KM: Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 143: 1375-1383, 1998. (Pubitemid 28559837)
11. DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB and Hidalgo M: Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 15: 1510-1516, 2004. (Pubitemid 39409742)
12. Weng LP, Smith WM, Brown JL and Eng C: PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet 10: 605-616, 2001. (Pubitemid 32229365)
13. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA and Trzaskos JM: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632, 1998. (Pubitemid 28334795)
14. Cocolakis E, Lemay S, Ali S and Lebrun JJ: The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem 276: 18430-18436, 2001.
15. Duval D, Malaise M, Reinhardt B, Kedinger C and Boeuf H: A p38 inhibitor allows to dissociate differentiation and apoptotic processes triggered upon LIF withdrawal in mouse embryonic stem cells. Cell Death Differ 11: 331-341, 2004. (Pubitemid 38313142)
16. Sun Y and Sinicrope FA: Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Mol Cancer Ther 4: 51-59, 2005. (Pubitemid 40268066)
17. Clark AS, West K, Streicher S and Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707-717, 2002.
18. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC and Yu D: PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127, 2004. (Pubitemid 39485684)
19. Faridi J, Wang L, Endemann G and Roth RA: Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 9: 2933-2939, 2003. (Pubitemid 36993252)
20. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E and Chibbar R: Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 18: 250-259, 2005. (Pubitemid 40188633)